Pharmacyclics is developing the
photosensitizer,
motexafin lutetium as Antrin for the potential treatment of restenosis and
atherosclerotic plaques,
Lutrin for the possible treatment of
cancer, and
Optrin for the possible treatment of
age-related macular degeneration (AMD). ANTRIN: A phase II multicenter, randomized, controlled study involving 375
peripheral artery disease (PAD) patients is being conducted in the US. It is designed to evaluate Antrin photoangioplasty as a primary treatment for PAD and for the prevention of restenosis following balloon angioplasty [341341,347151].
LUTRIN:
Lutrin is being developed for the possible treatment of a number of
cancers [348919]. In July 1997, the compound entered phase II trials for
breast cancer [323952,323929]. In August 2000, the compound was undergoing a phase IIb trial for advanced refractory
breast cancer [380234].
OPTRIN: In May 2000, Pharmacyclics reported preliminary results from an ongoing phase II dose-ranging study with
Optrin for the
photodynamic therapy of patients with AMD [365074].